Correction: Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study

In the published article, one of the eligibility criteria for the patients included in the study was not stated with the same level of detail as in the IRB-approved protocol.

A correction has been made to the Methods section, subsection Patients, paragraph 1:

“iii) those who had previously received DPP-4 inhibitors and were deemed by their treating physicians to require transition to a GLP-1 receptor agonist, subsequently initiated oral semaglutide at a starting dose of 3 mg, and, at an outpatient follow-up visit conducted at least 12 weeks after initiation, had no adherence- or tolerability-related barriers to continued treatment;”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Footnotes

Edited and reviewed by: Alessando Mattina, IRRCS ISMETT/UPMC Italy, Italy